The patent interference is related to certain pre-cooling technologies that CryoCor considers important to CryoCath’s cryoablation system. A patent interference is an administrative proceeding within the USPTO to
The approvals are for 10mg, 20mg, and 40mg dosage levels of omeprazole capsules under a mutual recognition procedure (MRP) that grants simultaneous authorizations throughout the EU. Bentley’s subsidiaries
The company is also initiating a post-approval clinical study of Orthovisc mini to gain additional clinical experience with regional opinion leaders who specialize in the treatment of osteoarthritis
The company has disclosed the activity of Arius’s anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). CD9 appears to be an important driver for leukemia and potentially other
The company expects its product to be launched in South Korea and Australia later this year. James Howard-Tripp, president and CEO, Labopharm, said: “South Korea and Australia are
Of the shares being sold, 3.22 million shares are being sold by the company and 83,000 shares are being sold by a selling stockholder. The company has granted
Eisai and Accenture Japan have reported that Accenture will provide Eisai with clinical data management services through its delivery center in Chennai. Starting full operation from February 13,
Biomoda’s non-invasive and cost-efficient screening technology identifies cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected
The patient was treated at the M D Anderson Cancer Center under the care of Johannes Wolff. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth
MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase I combination clinical trial with Taxotere for solid tumors, two Phase I/II combination trials
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.